Company profile for BioTheryX

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs. The identification of Cereblon (an E3 ligase) as a key target of the IMiDs® (the most successful class of anti-cancer drug in the world) showed that targeting protein degradation is a viable dru...
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs. The identification of Cereblon (an E3 ligase) as a key target of the IMiDs® (the most successful class of anti-cancer drug in the world) showed that targeting protein degradation is a viable drug development strategy that can lead to enormous commercial success. With unmatched commercial and scientific experience, the BioTheryX drug development team is building a set of high value assets in protein modulation

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
20 Cabin Ridge Road Chappaqua, NY 10514
Telephone
Telephone
(914) 490-5425
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/biotheryx-announces-completion-of-enrollment-in-phase-1a-clinical-trial-of-btx-9341-for-the-treatment-hrher2--breast-cancer-302616179.html

PR NEWSWIRE
17 Nov 2025

https://www.prnewswire.com/news-releases/texas-am-health-and-burstiq-partner-to-revolutionize-clinical-genomics-research-302199330.html

PR NEWSWIRE
17 Jul 2024

https://www.prnewswire.com/news-releases/biotheryx-announces-us-fda-clearance-of-investigational-new-drug-application-for-btx-9341-a-first-in-class-dual-bifunctional-degrader-of-cdk46-302137704.html

PR NEWSWIRE
07 May 2024

https://www.prnewswire.com/news-releases/biotheryx-to-present-new-preclinical-data-on-bifunctional-degraders-for-cdk46-and-sos1-at-2023-asco-annual-meeting-301835151.html

PR NEWSWIRE
25 May 2023

https://www.prnewswire.com/news-releases/biotheryx-presents-preclinical-cdk46-and-sos1-protein-degrader-data-at-aacr-2023-annual-meeting-301798000.html

PR NEWSWIRE
17 Apr 2023
Incyte taps Biotheryx for $360M molecular glue degrader deal
Incyte taps Biotheryx for $360M molecular glue degrader deal

06 Apr 2023

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/incyte-taps-biotheryx-360m-second-molecular-glue-degrader-deal-day

James Waldron FIERCE BIOTECH
06 Apr 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty